Increase in hepatic expression of SREBP-2 by gemfibrozil administration to rats.

Biochem Pharmacol

Unidad de Farmacologia y Famacognosia, Facultad de Farmacia, Universidad de Barcelona, Nucleo Universitario de Pedralbes, 08028, Barcelona, Spain.

Published: September 2001

It is well known that gemfibrozil increases the biliary output of cholesterol and phospholipids, but we have little knowledge about the impact these changes have on liver cholesterol and phospholipid biosynthetic pathways. In the present study, no changes were detected in liver lipids and CTP:phosphocholine cytidylyltransferase after gemfibrozil administration to rats. On the contrary, 3-hydroxy-3-methylglutaryl-CoA reductase mRNA (9.9-fold) and Rd activity (16.7-fold) and phosphatidate phosphohydrolase activity (1.7-fold) increased, while plasma apo B-cholesterol (40%) and triglyceride (43%) levels decreased. As a part of a compensatory homeostatic response, we report for the first time that gemfibrozil administration to rats increased the hepatic sterol regulatory element binding protein-2 (SREBP-2) mRNA (2.9-fold) and mature protein (2.2-fold) levels. An early increase in the transcriptional activity of SREBP-2 elicited by gemfibrozil administration might be responsible for the observed changes in HMG-CoA reductase, phosphatidate phosphohydrolase, and SREBP-2 expression.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-2952(01)00701-8DOI Listing

Publication Analysis

Top Keywords

gemfibrozil administration
16
administration rats
12
phosphatidate phosphohydrolase
8
gemfibrozil
5
increase hepatic
4
hepatic expression
4
srebp-2
4
expression srebp-2
4
srebp-2 gemfibrozil
4
administration
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!